"I'm all for this great effort by ImmunityBio to provide us with an alternative option,” says Suzanne B. Merrill, MD, FACS. For years, urologists and patients have dealt with the effects of the BCG ...

Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer ...

A panelist discusses how benign prostatic hyperplasia (BPH) management involves a comprehensive patient journey that encompasses initial diagnostic evaluation, tailored pharmacological interventions ...

The Visby Medical test is the first at-home, prescription-free diagnostic for chlamydia, gonorrhea, and trichomoniasis. It provides results in approximately 30 minutes using a self-collected vaginal ...

"For other health care professionals aiming to advocate for equitable changes within their system, it's really important to just start conversations about what you're noticing," says Hailey Frye.

"In a practice like mine, where approximately 30% of the practice is low testosterone, it'll have actually very little negative effect," says John P. Mulhall, MD. Following the FDA’s class-wide ...

“One important aspect to get across…is that access to this EAP is pretty easy," says Suzanne B. Merrill, MD, FACS. An expanded access program (EAP) to provide recombinant BCG (rBCG) in the US was ...

The FDA approved neoadjuvant durvalumab with gemcitabine and cisplatin, followed by adjuvant durvalumab, for muscle invasive bladder cancer (MIBC). Phase 3 NIAGARA trial results showed improved ...

Panelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize ...

“The impact on bone health is really significant with long-term androgen suppression," says Dr Louise Kostos. In a recent study of combination therapies for the treatment of locally advanced and ...

Panelists discuss how the phase 3 DORA trial investigates the combination of standard of care darolutamide with radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC), ...

"A lot of times…decreased desire is affected by everything else: pain with sex, orgasm, arousal. Because if none of that is good, then desire isn't going to be good either," says Anna Myers, CNP. In a ...